Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors

<p>Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.</p>

Na minha lista:
Detalhes bibliográficos
Autor principal: Martina S.J. McDermott (15206951) (author)
Outros Autores: Neil A. O'Brien (15206954) (author), Benjamin Hoffstrom (15206957) (author), KeWei Gong (15206960) (author), Ming Lu (15206963) (author), Jun Zhang (15206966) (author), Tong Luo (15206969) (author), Min Liang (15206972) (author), Weiping Jia (15206975) (author), Jenny J. Hong (15206978) (author), Kevin Chau (15206981) (author), Simon Davenport (15206984) (author), Bin Xie (15206987) (author), Michael F. Press (15206990) (author), Richard Panayiotou (15206993) (author), Abram Handly-Santana (15206996) (author), Joan S. Brugge (9710515) (author), Leonard Presta (15206999) (author), John Glaspy (15207002) (author), Dennis J. Slamon (15047067) (author)
Publicado em: 2025
Assuntos:
Cancer
Therapeutic Research and Development
Biological Agents & Therapies
Antibody-drug conjugates
Gynecological Cancers
Endometrial cancer
Ovarian cancer
Translational Research
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
Descrição
Resumo:<p>Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.</p>

Registros relacionados